Theriva Biologics, Inc.
TOVX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $7 | $7 | $829 |
| - Cash | $12 | $23 | $42 | $67 |
| + Debt | $2 | $2 | $2 | $2 |
| Enterprise Value | -$8 | -$14 | -$33 | $764 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$19 | -$22 | -$19 | -$14 |
| % Margin | – | – | – | – |
| Net Income | -$26 | -$18 | -$20 | -$14 |
| % Margin | – | – | – | – |
| EPS Diluted | -19.03 | -28.48 | -32.66 | -1.9 |
| % Growth | 33.2% | 12.8% | -1,618.9% | – |
| Operating Cash Flow | -$17 | -$19 | -$19 | -$13 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$17 | -$19 | -$19 | -$13 |